Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jean Haspel

Nurse Practitioner Atlantic City, NJ Nurse Practitioner

NPI 1932146750 CMS profile 10621925

1401 Atlantic Ave, Suite 2600, Atlantic City, NJ 08401

Open in the dashboard

General payments

$5,935

221 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jean Haspel of Atlantic City, NJ is reported in the CMS Open Payments database as having received $5,935 across 221 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,503 55
2024 General $992 32
2023 General $1,185 46
2022 General $1,135 53
2021 General $1,121 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jean Haspel
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Jean Haspel were reported at $1,503. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Jean Haspel Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,121 $135 $40–$426 $132
2022 $1,135 $152 $48–$470 $149
2023 $1,185 $166 $54–$529 $160
2024 $992 $173 $55–$556 $164
2025 $1,503 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Gilead Sciences, Inc. $1,753 75 payments
  2. ViiV Healthcare Company $1,563 56 payments
  3. AbbVie, Inc. $624 19 payments
  4. Braeburn Inc. $539 22 payments
  5. Alkermes, Inc. $527 10 payments
  6. Theratechnologies Inc. $413 12 payments
  7. Merck Sharp & Dohme Corporation $316 17 payments
  8. Indivior Inc. $77 5 payments
  9. Janssen Products, LP $50 1 payment
  10. Janssen Biotech, Inc. $31 2 payments
  11. Other $43 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,485 218 payments
  2. Consulting Fee $380 1 payment
  3. Education $70 2 payments
Products named General payments · program years 2021–2025
  1. CABENUVA $647 21 payments
  2. MAVYRET $624 19 payments
  3. BRIXADI $539 22 payments
  4. VIVITROL $527 10 payments
  5. DOVATO $440 24 payments
  6. Biktarvy $379 12 payments
  7. PIFELTRO $283 15 payments
  8. EGRIFTA SV $215 2 payments
  9. DELSTRIGO $205 15 payments
  10. ISENTRESS $184 14 payments
  11. Other $1,206 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,938

Median for Nurse Practitioner: 389

Drug cost

$5,336,259

Median for Nurse Practitioner: $21,885

Branded share of claims

82.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 413 $1,661,778
Triumeq Abacavir/Dolutegravir/Lamivudi Brand 135 $490,052
Tivicay Dolutegravir Sodium Brand 211 $449,119
Cabenuva Cabotegravir/Rilpivirine Brand 70 $445,434
Juluca Dolutegravir/Rilpivirine Brand 109 $396,230
Symtuza Darunavir/Cob/Emtri/Tenof Alaf Brand 81 $381,085
Prezcobix Darunavir/Cobicistat Brand 132 $302,587
Rukobia Fostemsavir Tromethamine Brand 35 $295,286
Genvoya Elviteg/Cob/Emtri/Tenof Alafen Brand 72 $280,789
Egrifta Sv Tesamorelin Acetate Brand 23 $184,458

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CABENUVA
  • ViiV Healthcare Company $192
$192 70 —
Biktarvy
  • Gilead Sciences, Inc. $186
$186 413 —
BRIXADI
  • Braeburn Inc. $131
$131 — —
RUKOBIA
  • ViiV Healthcare Company $98
$98 35 —
EGRIFTA SV
  • Theratechnologies Inc. $98
$98 23 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

221 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record